R ECENTLY, synthetic angiotensin II has become available for study. Page, Helmer, 1 Braun-Menendez, and co-workers 2 have demonstrated that this compound represents the reaction product of renin on the ao-globulin hypertensinogen. Intensive pharmacological studies conducted by the Cleveland group 3 ' 4i 3 and the Swiss 8 have verified these observations that synthetic angiotensin II is identical with the naturally occurring substance. The availability of this compound [Hypertensin-Ciba (Val-5-Angiotensin II-Asp-/?Amide)] prompted a comparison of its pressor and hemodynamic properties with those of norepinephrine in man.
Methods
The effect of intravenous infusions of angiotensin II and of norepinephrine on the arterial pressure and heart rate was studied in 17 normotensive and three hypertensive subjects. The normotensive subjects included eight young patients without cardiovascular renal disease, five with an elevated blood urea nitrogen, and four elderly subjects with generalized arteriosclerosis. The patients were in the fasting state and remained in the supine position throughout the experiment. Angiotensin II and norepinephrine bitartraie (Levophed) were administered as intravenous infusions. The concentration of angiotensin II was 0.5 ,ug./ml., and the concentration of nor-epinephrine was 4 /xg./ml. Both pressor substances were diluted in 5 per cent dextrose in water. The rates of infusion were regulated according to the increase in arterial pressure and the decrease in heart rate. The end point of the experiment was taken as a rise in mean arterial pressure in excess of 25 per cent. The arterial pressure was recorded by the usual auscultatory method. The mean arterial pressure was determined by the formula: systolic plus diastolic pressure divided by two. The arterial pressure and heart rate were recorded every 30 seconds during the infusions.
The cardiac index, plasma volume, and red-cell mass were determined in 10 normotensive patients without cardiovascular disease. The cardiac index was determined by the Stewart-Hamilton indicator-dilution method. 7 Following a blank sample, 30 to 50 (ic. of I 131 -HSA (human serum albumin) was added to the suspension of the patient's red cells which had been incubated with Cr 31 -RBC (labeled red blood cells) and washed three times in the standard fashion. Femoral arterial samples were drawn and collected in tubes containing dried hepnrin at two-second intervals during the first minute and then at 10, 15, 20, and 25 minutes after the injection of the isotopes for the determination of radioactivity. The plasma volume and red-cell mass were calibrated by extrapolating the radioactivity to the times of injection.
The radioactivity of both isotopes was counted on a well-type scintillation counter. Counts/min./ ml. were plotted on the ordinate, and the time in seconds on the abscissa of semilogarithmie paper. The integral of the indicator-dilution curves was determined according to Lillienfield and Kovach. 8 The cardiac index in ml./min. was calculated by dividing the amount of the indicator administered times 60 by the integral of the indicator-dilution curves.
During 15 of the above procedures, a 12-lead electrocardiogram was recorded before, during, and after the infusion of angiotensin II. In eight patients without cardiovascular disease, a 14 X 17-cm. x-ray of the chest was taken before and after the infusion of angiotensin II to give a rough index of change in the cardiac volume. The vital capacity was determined in six patients using a spirometer. The venous pressure was de- termiiied in seven patients. 9 The effect of angiotensin II and norepinephrine on the venous pressure was compared in five patients. In the latter patients, the arterial pressure was elevated to the same level with both pressor substances. The neck veins were carefully inspected during infusions of angiotensin II to determine changes in caliber. Similarly, careful ophthalmoscopie examination through dilated pupils was performed before and during the angiotensin II infusions to determine changes in the caliber of retinal arteries. The total peripheral resistance (TPR) expressed in dynes/em. 3 /see. was calculated from the following formula: T _ Mean arterial pressure (mm. Hg) Cardiac output (L./sec.) The effect of serial infusions of angiotensin II and Z-epinephrine on the cardiac output and total peripheral resistance was compared in five patients without cardiovascular disease. These procedures were then repeated using a combination Circulation Research, Volume IX, March 1901 of angiotensin II and Z-epinephrine in the same infusion. The dose of angiotensin II, both when used alone and in combination with i-epinephrine, was 0.015 to 0.0195 /xg./Kg./min. The dose of J-epinephrine was 0.015 /ng./Kg./min.
The effect of infusions of angiotensin II on serum sodium and potassium was studied in seven patients. The average increase in arterial pressure in these patients was 33 per cent. The electrolyte determinations were performed photometrically by the method of Berry, Chappell, and Barnes. 10 In five patients, renal-blood-flow determinations were performed using I 13l -Diodrast. u~13 A priming dose of 3 /xg./Kg. was followed by a sustaining dose of 0.05 /u.g./Kg./rnin., which was administered during a two-hour period. Venous samples were drawn at four-minute intervals and urine samples collected at 20-to 30-minute intervals. The radioactivity of urine and blood samples was counted in a well-type scintillation counter. The effective renal plasma flow was calculated from the formula: radioactivity of urine X output of urine radioactivity of whole blood sample Inulin and sodium para-aminohippurate (PAH) clearances were determined in five patients without cardiovascular disease. Inulin was determined by the method of Roe, Epstein, and Goldstein 14 and PAH by the method of Smith, Finkelstein, Aliminosa, Crawford, and Graber. 15 The control and the 24-hour clearance fractions represented an average of three clearance periods, while the remaining determinations represented one clearance period lasting one hour.
Results
The effect of intravenous infusions of angiotensin II and norepinephrine on the arterial pressure and the heart rate was compared in 17 normotensive aud 3 hypertensive patients. It can be noted in table 1 that angiotensin II was about 10 times as potent as norepinephrine. Thus 0.028 ± 0.007 /j.g./Kg./min. of angiotensin II produced an increase in arterial pressure similar to that produced by 0.27 ± 0.007 ^g./Kg./min. of epinephrine. The pressor responses to both agents were not significantly increased in the presence of uremia or hypertensive disease.
The rise in arterial pressure occurred au average of two and six-tenths minutes following discontinuation of angiotensin II lasted an average of three minutes after institution of norepinephrine. The arterial pressure returned to the base line an average of seven minutes after discontinuation of angiotensin II and an average of four minutes after discontinuation of norepinephrine. Following discontinuation of angiotensin II, postural hypotension (15 to 30 per cent below the control standing mean arterial pressure) occurred in six patients. A comparable degree of postural hypotension occurred in four patients following discontinuation of norepinephrine. The postural hypotension following discontinuation of angiotensin II lasted 18 to 24 hours, as compared with 4 to 6 hours after discontinuation of norepinephrine. The responses of the heart, rate during angiotensin II and norepinephrine were similar : Both agents produced significant bradycardia in patients without cardiovascular disease, while a decreased bradycrotic response was noted in the patients with arteriosclerosis. The bradycardia following either agent could be blocked by 1 mg. of atropine.
The rise in arterial pressure due to angiotensin II was not associated with significant change in the vital capacity (6 patients) or in the caliber of the retinal arteries (30 patients). No side effects were noted during these infusions. A 42 ± 7 per cent increase in mean arterial pressure in 11 normotensive patients given angiotensin II was associated with a reduction in cardiac index from an average of 3.34 ± .55 to 2.56 ± .53 L./min./M 2 , a 24 per cent average reduction, with no change in the plasma volume or red-cell mass. If the one patient who demonstrated a 35 per cent decrease in cardiac index was excluded, the average percentage decrease of cardiac index would be 14 per cent.
A 37 ± 15 per cent increase in mean arterial pressure in seven normotensive patients with augiotensin II was associated with a 52 ± 30 per cent average increase in venous pressure. Table 2 shows that the increase in venous pressure following norepinephrine was almost twice that following angiotensin II. Table 3 demonstrates that infusions of angiotensin II seem to have no immediate predictable or consistent effect on serum sodium or potassium.
The cardiovascular response of five normotensive patients to infusions of angiotensin II and Z-epinephrine can be observed in table 4. The increase of arterial pressure during angiotensin II administration was associated with a slight decrease in cardiac output and a striking increase in total peripheral resistance. The addition of equivalent amounts of epinephrine to the infusion resulted in a slight fall in the arterial pressure, a striking increase in cardiac output, and a fall in the total peripheral resistance from the elevated levels during administration of angiotensin II. The effect of angiotensin II on the renal hemodynamics is outlined in tables 5 and 6, and in figure 1 . A 24-hour infusion of angiotensin II in six normotensive patients was associated with a slight decrease in urinary output (table 5). Table 6 shows that the effective renal plasma flow (I 131 -Diodrast) was reduced throughout the entire angiotensin II infusion. Figure 1 demonstrates that both the inulin and PAH clearances are significantly decreased during the angiotensin II infusion, the reduction in PAH being greater than the reduction in inulin. The filtration fraction was, therefore, increased.
Thirteen patients in shock received augiotensin II therapeutically for periods varying from one hour to 14 days. Their diagnoses included septicemia (4), cerebral vascular accident (3), gastrointestinal bleeding (2), and one instance each of hepatic coma, eareinomatosis, pulmonary infarction, and methonal poisoning. Excluding patients with terminal disease who did not respond to as much as 3 to 4 jxg. of angiotensin II per minute, the average effective dose was 0.035 //.g./Kg./min. In patients who responded initially, no tachyphylaxis or drug resistance was noted. In fact, less angiotensin II was necessary on succeeding days. An increase in the urinary output was noted in every patient following the first 24 hours of infusion. No cardiac arrhythmias were noted.
Discussion The data presented demonstrate that in normotensive subjects angiotensin II is approximately 10 times as potent as norepinephrine, which it resembles hemodynamically. 16 The rise in systolic pressure in patients without cardiovascular disease is associated with: (1) a significant increase in diastolic pressure, (2) an increase in venous pressure, (3) a decrease in heart rate, (4) a slight decrease in cardiac output, and (5) a striking increase in total peripheral resistance. It would seem then that, like norepinephrtne, the primary action of angiotensin II is to produce an intense overall vasoconstriction, and that this vasoconstrictor action can be completely blocked by the simultaneous administration of equal doses of lepinephrine (table 41. Similar to norepinephrine, the bradycardia accompanying angiotensin II infusion can be blocked by atropine. It is also interesting that the decreased bradycrotic response during norepinephrine previously observed in patients with vascular disease 17 was also noted in patients during angiotensin II infusion (table  1) . Unlike norepinephrine, however, extrasj'stoles and other arrhythmias did not accompany infusions of angiotensin II. Table 4 demonstrates that angiotensin II infusion is associated with a slight decrease in cardiac output. Comparable increases in mean arterial pressure during norepinephrine administration in this laboratory have not been associated with change of the cardiac output. ls Using the Fick method, Sancetta 10 found angiotensin II caused no significant change in cardiac output. The explanation for these discrepancies is not evident.
Studies of the renal hemodynamics during angiotensin II infusion in subjects without cardiovascular disease demonstrate: (1) a slight decrease in urinary volume, (2) a marked decrease in renal blood flow, (3) a moderate decrease in filtration rate, and (4) an increase in filtration fraction. It should be stressed that the infusions of angiotensin II in the patients studied here were continued over a 24-hour period. The observation of greater decrease in renal blood flow during angiotensin II is similar to the findings of Bock and Kriecke 20 who administered augiotensin II to patients for 54 minutes. The decrease in PAH at the end of 24 hours of angiotensin II in patients presented here is no greater than at the end of 2 hours. The fact that a similar persistent decrease was noted when the renal plasma flow was measured by the radioactive method substantiates the ob-PINNERTY, MASSARO, CHUPKOVICH, TUCKMAN servation that decrease in renal blood flow persists as long as the angiotensin II is continued. Although renal blood flow measurements were not determined following discontinuance of angiotensin II in the patients studied here, the data of Bock and Kriecke 20 demonstrate a prompt rise in these clearances to above control levels one hour after discontinuance of angiotensin II. It would seem, then, that angiotensin II alters the renal hemodynamics only during the period of its administration.
Preliminary observations on the use of angiotensin II in patients in shock suggest that it is two to three times as potent as norepinephrine. This observation may be important from the therapeutic standpoint, since less parenteral fluid would be needed to control the arterial pressure. Experience thus far with angiotensin II both in the experiments outlined above and in treating shock suggests that the desired level of arterial pressure is easier to achieve and maintain with angiotensin II than with norepinephrine. Of particular interest also was the lack of development of drug resistance in three patients who received angiotensin II continuously for 10, 12, and 14 days, respectively. In these patients there was a decrease in the dose of angiotensin II needed to maintain the arterial pressure on successive days, an increase in urinary output, and a decrease in blood urea nitrogen. During the long-term therapy of two of these latter patients, and in six other instances during the experiments reported above, the intravenous infusion of angiotensin II inadvertently infiltrated into the subcutaneous tissue. Xo sloughing occurred.
Summary These data demonstrate that in normal subjects angiotensin II is 10 times as potent as norepinephrine, \vhich it resembles hemodynamically. An increase in the systolic pressure is associated with significant increase in diastolie pressure, increase in venous pressure, decrease in heart rate, slight decrease in cardiac output with striking increase in total peripheral resistance, decrease in renal blood flow, decreased glomerular filtration rate, increase in filtration fraction, and slight decrease in urinary volume.
Preliminary studies of patients in shock suggest that angiotensin II is two or three times as potent as norepinephrine. Continuous administration is not associated with the development of resistance or tachyphylaxis, nor does sloughing of tissues occur when there is leakage outside the vein.
